Background: EBAG9 is a type III transmembrane protein that is predominantly located in the Golgi. It induces apoptosis of natural killer (NK)/T cells and plays a role in immune invasion, possibly in relation to Epstein-Bar virus infection. EBAG9 is abundantly expressed in prostate cancer cells when compared to normal epithelial cells, and immunodetection of EBAG9 expression can be a negative prognostic indicator for patients with prostate cancer.
Description: Rabbit polyclonal to EBAG9
Immunogen: KLH conjugated synthetic peptide derived from EBAG9
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 24 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.